{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:03:54Z","timestamp":1791461034833,"version":"4.3.4"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Poor treatment adherence is common in schizophrenia and constitutes a major risk factor for relapse and clinical instability. Long-acting injectable (LAI) antipsychotics are frequently prescribed to mitigate this risk; however, their use can be associated with rare but serious adverse events, including neuroleptic malignant syndrome (NMS), with certain atypical presentations posing considerable diagnostic challenges. We report the case of a 51-year-old patient with schizophrenia who, during hospitalization for a psychotic relapse following prolonged refusal of all oral medications, received an intramuscular injection of paliperidone palmitate. Within a few days, the patient experienced a rapid clinical deterioration, characterized by hyperthermia (38 \u00b0C), tachycardia (120 bpm), generalized muscular rigidity, mutism, confusion, dehydration, and refusal of oral intake. No obvious precipitating factors, including infectious or environmental triggers, were identified. Initial laboratory workup revealed marked creatine phosphokinase elevation (1700 U\/L), hyperferritinemia, and evidence of a pulmonary infiltrate on chest imaging. Given this constellation of clinical and laboratory findings, a diagnosis of neuroleptic malignant syndrome (NMS) was considered. The lack of improvement with antibiotic therapy alone, the persistence of extrapyramidal symptoms, and the ongoing laboratory abnormalities supported the diagnosis of an atypical form of NMS. The patient was transferred to the intensive care unit, where symptomatic management\u2014including intravenous rehydration, antipyretics, empirical antibiotic therapy, and diazepam\u2014resulted in gradual clinical improvement. Complete recovery was achieved after five weeks of hospitalization. Antipsychotic therapy was cautiously reintroduced with olanzapine, which was well tolerated and not associated with any recurrence of symptoms. This case illustrates the diagnostic and therapeutic challenges of neuroleptic malignant syndrome associated with long-acting injectable antipsychotics and emphasizes the need for close and prolonged monitoring in patients receiving these formulations.<\/jats:p>","DOI":"10.3389\/fpsyt.2026.1718815","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T11:48:58Z","timestamp":1770810538000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case Report: Atypical neuroleptic malignant syndrome induced by paliperidone palmitate\u2014diagnostic challenges and clinical considerations"],"prefix":"10.3389","volume":"17","author":[{"given":"Omar","family":"El Oumary","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Ibn Zohr University","place":["Agadir, Morocco"]},{"name":"Innovation and Ethics in Clinical Neuroscience (NICE), Research Laboratory \u201cKidney, Endocrinology, Gastroenterology, Neurosciences and Ethics\u201d (REGNE), Faculty of Medicine, Ibn Zohr University","place":["Agadir, Morocco"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hicham","family":"Laaraj","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Ibn Zohr University","place":["Agadir, Morocco"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Ouhamou","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Ibn Zohr University","place":["Agadir, Morocco"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Mouhadi","sequence":"additional","affiliation":[{"name":"Innovation and Ethics in Clinical Neuroscience (NICE), Research Laboratory \u201cKidney, Endocrinology, Gastroenterology, Neurosciences and Ethics\u201d (REGNE), Faculty of Medicine, Ibn Zohr University","place":["Agadir, Morocco"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalal","family":"Doufik","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Ibn Zohr University","place":["Agadir, Morocco"]},{"name":"Innovation and Ethics in Clinical Neuroscience (NICE), Research Laboratory \u201cKidney, Endocrinology, Gastroenterology, Neurosciences and Ethics\u201d (REGNE), Faculty of Medicine, Ibn Zohr University","place":["Agadir, Morocco"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija","family":"Akebour","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Ibn Zohr University","place":["Agadir, Morocco"]},{"name":"Innovation and Ethics in Clinical Neuroscience (NICE), Research Laboratory \u201cKidney, Endocrinology, Gastroenterology, Neurosciences and Ethics\u201d (REGNE), Faculty of Medicine, Ibn Zohr University","place":["Agadir, Morocco"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saliha","family":"Hamri","sequence":"additional","affiliation":[{"name":"Innovation and Ethics in Clinical Neuroscience (NICE), Research Laboratory \u201cKidney, Endocrinology, Gastroenterology, Neurosciences and Ethics\u201d (REGNE), Faculty of Medicine, Ibn Zohr University","place":["Agadir, Morocco"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Rammouz","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Ibn Zohr University","place":["Agadir, Morocco"]},{"name":"Innovation and Ethics in Clinical Neuroscience (NICE), Research Laboratory \u201cKidney, Endocrinology, Gastroenterology, Neurosciences and Ethics\u201d (REGNE), Faculty of Medicine, Ibn Zohr University","place":["Agadir, Morocco"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1186\/s12888-025-07273-6","article-title":"Trends and cross-country inequalities in schizophrenia from 1990 to 2021, with prediction to 2035: a systematic analysis of the global burden of disease study 2021","volume":"25","author":"Luo","year":"2025","journal-title":"BMC Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e2432401","DOI":"10.1001\/jamanetworkopen.2024.32401","article-title":"Risk factors for natural cause mortality in schizophrenia","volume":"7","author":"Dickerson","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1177\/87551225231153541","article-title":"Invega hafyera (Paliperidone palmitate): extended release injectable suspension for patients with schizophrenia","volume":"39","author":"Peters","year":"2023","journal-title":"J Pharm Technol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.3360","article-title":"Schizophrenia\u2014an overview","volume":"77","author":"McCutcheon","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/20451253241257062","article-title":"Efficacy and safety of long-acting injectable versus oral antipsychotics in the treatment of patients with early-phase schizophrenia-spectrum disorders: a systematic review and meta-analysis","volume":"14","author":"Vita","year":"2024","journal-title":"Ther Adv Psychopharmacol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-03075-6","article-title":"Real-world effectiveness of long-acting injectable and oral antipsychotic agents in US medicare patients with schizophrenia","volume":"42","author":"Li","year":"2025","journal-title":"Adv Ther"},{"key":"B7","volume-title":"The Maudsley Prescribing Guidelines in Psychiatry","author":"Taylor","year":"2020"},{"key":"B8","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.119481","article-title":"Investigation into neuroleptic Malignant syndrome triggered by atypical antipsychotics: Insights from FDA adverse event reporting system database","volume":"386","author":"He","year":"2025","journal-title":"J Affect Disord"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000507","article-title":"Atypical neuroleptic Malignant syndrome associated with paliperidone long acting injection: a case report","volume":"36","author":"Langley DeGroot","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1503\/jpn.200015","article-title":"Long-acting injectable antipsychotics: choosing the right dose","volume":"45","author":"Carlone","year":"2020","journal-title":"J Psychiatry Neurosci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e41171","DOI":"10.1097\/MD.0000000000041171","article-title":"Paliperidone induced neuroleptic Malignant syndrome: a case report","volume":"104","author":"Unal","year":"2025","journal-title":"Med (Baltimore)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923060-00003","article-title":"Neuroleptic Malignant syndrome associated with atypical antipsychotic drugs","volume":"23","author":"Trollor","year":"2009","journal-title":"CNS Drugs"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001019","article-title":"Low incidence of neuroleptic Malignant syndrome associated with paliperidone palmitate long-acting injectable: a database report and case study","volume":"39","author":"Kane","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"B15","article-title":"Neuroleptic Malignant syndrome","volume-title":"StatPearls","author":"Simon","year":"2024"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2019.06.009","article-title":"Atypical neuroleptic Malignant syndrome: A systematic review of case reports","volume":"60","author":"Singhai","year":"2019","journal-title":"Gen Hosp Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2025.1552232","article-title":"Virus-induced rhabdomyolysis ranging from mild course to acute renal injury, hyperferritinemia and poor outcome: a case series of four pediatric patients","volume":"13","author":"Van der Zee","year":"2025","journal-title":"Front Pediatr"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S407259","article-title":"Paliperidone palmitate versus risperidone long acting injectable in patients with schizophrenia: a meta-analysis of efficacy and safety","volume":"19","author":"Zhao","year":"2023","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13359","article-title":"A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic Malignant syndrome","volume":"144","author":"Guinart","year":"2021","journal-title":"Acta Psychiatr Scand"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1136\/ejhpharm-2021-002901","article-title":"Risperidone is not only a prodrug: psychosis induced by medication switch from risperidone to paliperidone \u2013 a case report","volume":"30","author":"Dagenais Beaul\u00e9","year":"2021","journal-title":"Eur J Hosp Pharm Sci Pract"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2404606","article-title":"Neuroleptic Malignant syndrome","volume":"391","author":"Wijdicks","year":"2024","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.699748","article-title":"Paliperidone 3-month injection for treatment of schizophrenia: A narrative review","volume":"12","author":"Edinoff","year":"2021","journal-title":"Front Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint13030035","article-title":"Paliperidone to treat psychotic disorders \u2013 pharmacology and receptor profile","volume":"13","author":"Minwalla","year":"2021","journal-title":"Neurol Int"},{"key":"B24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40263-020-00779-5","article-title":"Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview","volume":"35","author":"Correll","year":"2021","journal-title":"CNS Drugs"},{"key":"B25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12888-025-06493-0","article-title":"A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases","volume":"25","author":"Lou","year":"2025","journal-title":"BMC Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.18773\/austprescr.2019.014","article-title":"Drug-induced movement disorders","volume":"42","author":"Duma","year":"2019","journal-title":"Aust Prescr"},{"key":"B27","doi-asserted-by":"publisher","first-page":"244","DOI":"10.55697\/tnd.2025.281","article-title":"Management of neuroleptic Malignant syndrome induced by paliperidone: A case report of multidisciplinary treatment approaches, including apomorphine","volume":"31","author":"G\u00fcltekin","year":"2025","journal-title":"Turk J Neurol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12315","article-title":"The management challenges of a case with Flupentixol-induced neuroleptic Malignant syndrome","volume":"43","author":"Elyasi","year":"2023","journal-title":"Neuropsychopharmacol Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X241229008","article-title":"Catatonia-related adverse outcomes after long-acting injectable antipsychotics: Case series","volume":"12","author":"Dragonetti","year":"2024","journal-title":"SAGE Open Med Case Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.12740\/PP\/OnlineFirst\/138338","article-title":"Malignant complications of masturbation \u2013 a case study","volume":"57","author":"M\u0119drala","year":"2023","journal-title":"Psychiatr Pol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.5080\/u26535","article-title":"A severe neuroleptic Malignant syndrome treated with daily electroconvulsive therapy: A case report","volume":"33","author":"Aki","year":"2022","journal-title":"Turk Psikiyatri Derg"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00718","article-title":"Risperidone-associated neuroleptic Malignant syndrome in an inpatient with schizophrenia, with successful rechallenge and 3 year follow-up","volume":"9","author":"Chen","year":"2018","journal-title":"Front Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.17l02125","article-title":"Neuroleptic Malignant syndrome after early administration of risperidone long-acting injection","volume":"19","author":"Mitchell","year":"2017","journal-title":"Prim Care Companion CNS Disord"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.encep.2016.01.001","article-title":"Syndrome Malin des neuroleptiques et difficult\u00e9s diagnostiques: \u00e0 propos d\u2019un cas","volume":"42","author":"Khouri","year":"2016","journal-title":"L\u2019Enc\u00e9phale"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000426180.89572.51","article-title":"Neuroleptic Malignant syndrome associated with risperidone long-acting injection: a case report","volume":"33","author":"Yamashita","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"B36","first-page":"78","article-title":"Afebrile Neuroleptic Malignant Syndrome associated with Fluphenazine decanoate: A case report","volume":"5","author":"Assareh","year":"2010","journal-title":"Iran J Psychiatry"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/15622970701714347","article-title":"Zuclopenthixol-induced neuroleptic Malignant syndrome presenting as fever of unknown origin, hyperglycaemia and acute myocardial infarction in a 60-year-old man","volume":"10","author":"Varoglu","year":"2009","journal-title":"World J Biol Psychiatry"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/15563650601031692","article-title":"Zuclopenthixol-induced neuroleptic Malignant syndrome in an adolescent girl","volume":"45","author":"Erermis","year":"2007","journal-title":"Clin Toxicol (Phila)"},{"key":"B39","article-title":"The life threatening adverse effects of psychotropic drugs: a case report","volume":"17","author":"Tiryaki","year":"2006","journal-title":"Turk Psikiyatri Derg"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.18.1.131","article-title":"Use of intravenous valproate in a patient with neuroleptic Malignant syndrome","volume":"18","author":"Tadke","year":"2006","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.52965\/001c.37530","article-title":"Silent neuroleptic Malignant syndrome: a case report of atypical antipsychotic induced elevation of creatinine kinase and altered mental status","volume":"5","author":"Edinoff","year":"2022","journal-title":"J Healthc Med Pract"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8879333","article-title":"Development of neuroleptic Malignant syndrome in a patient with Lewy body dementia after intramuscular administration of paliperidone","volume":"2021","author":"Yeung","year":"2021","journal-title":"Case Rep Neurol Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001370","article-title":"Late-onset neuroleptic Malignant syndrome associated with paliperidone long-acting injection and lithium: a case report","volume":"41","author":"Netcheva","year":"2021","journal-title":"J Clin Psychopharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2587963","article-title":"Paliperidone inducing concomitantly syndrome of inappropriate antidiuretic hormone, neuroleptic Malignant syndrome, and rhabdomyolysis","volume":"2016","author":"Kaur","year":"2016","journal-title":"Case Rep Endocrinol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.23.1.jnpe14","article-title":"Paliperidone-induced neuroleptic Malignant syndrome","volume":"23","author":"Nayak","year":"2011","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp090243","article-title":"Neuroleptic Malignant syndrome secondary to aripiprazole initiation in a clozapine-intolerant patient","volume":"67","author":"Patel","year":"2010","journal-title":"Am J Health Syst Pharm"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1718815\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T11:49:01Z","timestamp":1770810541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1718815\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":46,"alternative-id":["10.3389\/fpsyt.2026.1718815"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1718815","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"article-number":"1718815"}}